Alvotech acquires Xbrane's R&D operations in Sweden and biosimilar candidate XB003
Source: SeekingAlpha
2025-03-20 04:09:21 ET
More on Alvotech
- Alvotech and Dr. Reddy’s biosimilar for Amgen's Prolia under FDA review
- Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara
- Seeking Alpha’s Quant Rating on Alvotech
- Historical earnings data for Alvotech
- Financial information for Alvotech
Read the full article on Seeking Alpha
For further details see:
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003
Alvotech
NASDAQ: ALVO
ALVO Trading
-6.23% G/L:
$3.01 Last:
679,105 Volume:
$3.23 Open:
ALVO Latest News
May 11, 2026 04:30:00 am
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
